Fwd: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
To: mesothelioma77@gmail.com


[1]J Clin Oncol. 2008 Jul 20; 26(21): 3567-72
Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL

PURPOSE: Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). Pemetrexed and gemcitabine are synergistic in preclinical models, but the activity of this combination in MPeM is unknown. This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM. PATIENTS AND METHODS: Treatment consisted of gemcitabine 1,250 mg/m(2) on days 1 and 8, and pemetrexed 500 mg/m(2) on day 8, administered immediately before gemcitabine. Treatment was repeated every 21 days for six cycles or until disease progression. All patients received folic acid, vitamin B(12), and dexamethasone supplementation. End points included tumor response, toxicity, time to disease progression (TTPD), and overall survival (OS). Disease control rate (DCR) was also calculated. RESULTS: Twenty patients were enrolled between December 2002 and May 2004. The confirmed response rate was 15% (95% CI, 3.2% to 37.9%), with three patients experiencing a partial response. The DCR was 50% (95% CI, 27.2% to 72.8%). The most common grade 3 to 4 nonhematologic toxicities included fatigue (20%), constipation (10%), vomiting (10%), and dehydration (10%). Hematologic toxicities included grade 3 to 4 neutropenia (60%) and febrile neutropenia (10%). One patient death was attributed to treatment. Median TTPD and OS times were 10.4 months and 26.8 months, respectively. CONCLUSION: The combination of pemetrexed plus gemcitabine was active in patients with MPeM with a notably high incidence of neutropenia. Median TTPD and OS seem promising. This regimen may provide an alternative to standard therapies, especially for patients who cannot tolerate a platinum-based regimen.



___
Source: http://www.hubmed.org/display.cgi?uids=18640937
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Gene test may predict lung cancer survival (Cancerfacts.com)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Gene test may predict lung cancer survival (Cancerfacts.com)
To: mesothelioma77@gmail.com


ANN ARBOR, Mich. – July 21, 2008 – An analysis involving a specific set of genes can be used to predict which lung cancer patients will have the poorest likelihood of survival, researchers say. The finding could one day lead to a test that would help determine who needs more aggressive treatment.

Tue, 22 Jul 2008 07:38:53 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12dr8df53/*http%3A//www.cancerfacts.com/Home_News.asp?NewsId=2339&CB=14&CancerTypeId=4
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: ORIGINAL ARTICLE: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (New England Journal of Medicine)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: ORIGINAL ARTICLE: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells (New England Journal of Medicine)
To: mesothelioma77@gmail.com


This study describes a method for capturing circulating tumor cells in patients with non-small-cell lung cancer with the use of antibody tethered to microposts. The isolated cells were of sufficient quantity and purity to genotype and thus could feasibly be used to guide genotype-specific treatment.

Wed, 23 Jul 2008 21:37:13 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12bru2hss/*http%3A//content.nejm.org/cgi/content/short/359/4/366?rss=1&query=current
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Mesothelioma and Personal Injury Lawyers in Jacksonville, Florida

---------- Forwarded message ----------
From: Soapbox on MSN Video - Top Search Results For: mesothelioma <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:12 AM
Subject: Mesothelioma and Personal Injury Lawyers in Jacksonville, Florida
To: mesothelioma77@gmail.com


[1][2]

www.terrellhogan.com – Located in Jacksonville, Florida and serving all of North Florida, the mesothelioma and personal injury lawyers of Terrell Hogan have extensive experience in this type law and has handled thousands of cases on behalf of its clients.

Views: 0

Rating: [3]

Uploaded On: Tue, 22 Jul 2008 20:33:34 -07:00

Tue, 22 Jul 2008 20:33:34 -07:00

* Attachment, application/x-shockwave-flash: [4]Download
___
Source: http://video.msn.com/video.aspx?vid=aafa33de-73b4-41b9-b3d9-d38f68af6a81
--
 ~
Powered by [8]RssFwd, a service of [9]Blue Sky Factory, Inc

 

Fwd: Response to Senator Kennedy, Unabridged - Cape Cod Today

---------- Forwarded message ----------
From: car insurance qoutes - Live Search News <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:12 AM
Subject: Response to Senator Kennedy, Unabridged - Cape Cod Today
To: mesothelioma77@gmail.com


F irst, let me say that as a proud liberal, I am and have been an ardent supporter of Senator Kennedy and his initiatives of social and economic justice and one of his more vocal supporters. However, on the issue of siting Cape Wind, I believe he has ...

Wed, 09 Jul 2008 00:59:00 GMT

___
Source: http://www.capecodtoday.com/blogs/index.php/2007/08/09/repsonse_to_senator_kennedy_unabridged?blog=68
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Genomic Characterisation, Chromosomal Assignment and in Vivo Localisation of the Canine High Mobility Group A1 (HMGA1) Gene.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Genomic Characterisation, Chromosomal Assignment and in Vivo Localisation of the Canine High Mobility Group A1 (HMGA1) Gene.
To: mesothelioma77@gmail.com


[1]BMC Genet. 2008 Jul 23; 9(1): 49
Beuing C, Soller JT, Muth M, Wagner S, Dolf G, Schelling C, Richter A, Willenbrock S, Reimann-Berg N, Winkler S, Nolte I, Bullerdiek J, Murua Escobar H

ABSTRACT: BACKGROUND: The high mobility group A1 proteins (HMGA1a/HMGA1b) are highly conserved between mammalian species and widely described as participating in various cellular processes. By inducing DNA conformation changes the HMGA1 proteins indirectly influence the binding of various transcription factors and therefore effect the transcription regulation. In humans chromosomal aberrations affecting the HMGA1 gene locus on HSA 6p21 were described to be the cause for various benign mesenchymal tumours while high titres of HMGA1 proteins were shown to be associated with the neoplastic potential of various types of cancer. Interestingly, the absence of HMGA1 proteins was shown to cause insulin resistance and diabetes in humans and mice. Due to the various similarities in biology and presentation of human and canine cancers the dog has joined the common rodent animal model for therapeutic and preclinical studies. Accordingly, the canine genome was sequenced completely twice but unfortunately this could not solve the structure of canine HMGA1 gene. RESULTS: Herein we report the characterisation of the genomic structure of the canine HMGA1 gene consisting of 7 exons and 6 introns spanning in total 9524bp, the in vivo localisation of the HMGA1 protein to the nucleus, and a chromosomal assignment of the gene by FISH to CFA12q11. Additionally, we evaluated a described canine HMGA1 exon 6 SNP in 55 Dachshunds. CONCLUSIONS: The performed characterisations will make comparative analyses of aberrations affecting the human and canine gene and proteins possible, thereby providing a basis for revealing mechanisms involved in HMGA1 related pathogenesis in both species.



___
Source: http://www.hubmed.org/display.cgi?uids=18651940
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.
To: mesothelioma77@gmail.com


[1]Ann Surg. 2008 Aug; 248(2): 280-5
Zork NM, Komenaka IK, Pennington RE, Bowling MW, Norton LE, Clare SE, Goulet RJ

OBJECTIVE: The impact of breast surgeons on short-term outcomes in breast cancer care was compared at a single institution. SUMMARY BACKGROUND DATA: Many studies have demonstrated a correlation between high procedural volume and lower mortality in technically challenging procedures. Breast cancer treatment has significant impact on patient behavior, psychology, and appearance. Therefore, evaluation of outcomes cannot be limited to only operative mortality and morbidity. We sought to determine the effect of dedicated breast cancer surgeons on short-term outcomes at a single institution. METHODS: Wishard Memorial Hospital is the county hospital affiliated with the Indiana University School of Medicine. A retrospective review was performed of all patients from January 1, 1997, to February 28, 2006. On July 1, 2003, coverage for the Breast Clinic was changed from general surgeons (G) to breast surgeons (B). There were 596 patients included in the study period. RESULTS: There were no significant differences in patient demographics or disease characteristics between the 2 time periods. For early stage (stage I and II) breast cancer, a higher percentage of patients underwent breast conservation in the breast surgeon period than in the general surgeon period (P = 0.04). Lumpectomy margins in breast conserving operations during the G period were more often positive (P = 0.025) or close (

___
Source: http://www.hubmed.org/display.cgi?uids=18650639
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults.
To: mesothelioma77@gmail.com


[1]Cochrane Database Syst Rev. 2008; CD006276
Robb KA, Bennett MI, Johnson MI, Simpson KJ, Oxberry SG

BACKGROUND: Cancer-related pain is complex and multi-dimensional but the mainstay of cancer pain management has predominately used a biomedical approach. There is a need for non-pharmacological and innovative approaches. Transcutaneous Electric Nerve Stimulation (TENS) may have a role for a significant number of patients but the effectiveness of TENS is currently unknown. OBJECTIVES: The aim of this systematic review was to determine the effectiveness of TENS for cancer-related pain in adults. SEARCH STRATEGY: We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL, PsychINFO, AMED and PEDRO databases (11/04/08). SELECTION CRITERIA: Only randomised controlled trials (RCTS) investigating the use of TENS for the management of cancer-related pain in adults were included. DATA COLLECTION AND ANALYSIS: The search strategy identified 37 possible published studies which were divided between two pairs of review authors that decided on study selection. A study eligibility form was used to screen each abstract and where study eligibility could not be determined from the abstract, the full paper was obtained and assessed by one pair of review authors. A standardised data extraction sheet was used to collect information on the studies and the quality of the studies was assessed independently by two review authors using the validated five-point Oxford Quality Scale. Final scores were discussed and agreed between all four review authors. The small sample sizes and differences in patient study populations of the two included studies prevented meta-analysis. MAIN RESULTS: Only two RCTs met the eligibility criteria (64 participants). These studies were heterogenous with respect to study population, sample size, study design, methodological quality, mode of TENS, treatment duration, method of administration and outcome measures used. In one RCT, there were no significant differences between TENS and placebo in women with chronic pain secondary to breast cancer treatment. In the other RCT, there were no significant differences between acupuncture-type TENS and sham in palliative care patients; this study was underpowered. AUTHORS' CONCLUSIONS: The results of this systematic review are inconclusive due to a lack of suitable RCTs. Large multi-centre RCTs are required to assess the value of TENS in the management of cancer-related pain in adults.



___
Source: http://www.hubmed.org/display.cgi?uids=18646140
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc